Excision BioTherapeutics Completes $60 Million Financing to Advance CRISPR-Based Infectious Disease Programs

SAN FRANCISCO, Feb. 17, 2021 (GLOBE NEWSWIRE) — Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the completion of a $60 million financing. The proceeds will be used to advance Excision’s lead candidate, EBT-101, into a Phase 1/2 clinical trial in patients with chronic HIV infection. […]